Zarontin 250 mg/5 ml Syrup
Authorisation PA22644/005/001 · Essential Pharma (M) Limited
- Licence holder
- Essential Pharma (M) Limited (all products →)
- Active substance
- Ethosuximide
- Dosage form
- Syrup
- Route of administration
- Oral use
- ATC codes
- N03AD, N03AD01
- First authorised
- 04/11/2016
- Prescription status
- Product subject to prescription which may be renewed (B)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Ethosuximide: supply and approvals
4 authorised products on the HPRA list contain Ethosuximide. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 20 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 20 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 20 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 10 years (since 4 November 2016). The HPRA list marks it as marketed in Ireland.
Other medicines with Ethosuximide in Ireland
3 other products on the HPRA list contain Ethosuximide, from 3 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Zarontin 250 mg/5 ml Syrup | PCO Manufacturing Ltd. | Parallel import (PPA) | Not stated |
| Zarontin 250 mg/5 ml Syrup | IMED Healthcare Ltd., | Parallel import (PPA) | Not stated |
| Zarontin 250mg/5ml Syrup | Originalis B.V. | Parallel import (PPA) | Not stated |
The licence holder
Essential Pharma (M) Limited holds 8 products on the HPRA list, with 5 different active substances; 1 of the products is marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.